Hydroxychloroquine fails as postexposure prophylaxis for COVID-19
However, the trial did have limitations, researchers note
Read Moreby Selina McKee | Jun 4, 2020 | News | 0
However, the trial did have limitations, researchers note
Read Moreby Selina McKee | Oct 5, 2018 | News | 0
Roche’s Hemlibra has been approved in the US for routine prophylaxis of bleeding episodes patients with haemophilia A without factor VIII inhibitors.
Read Moreby Selina McKee | Sep 20, 2018 | News | 0
US regulators have turned down Pharming’s application to expand the approved uses of Ruconest to include prophylaxis in patients with hereditary angioedema (HAE).
Read Moreby Selina McKee | Dec 6, 2016 | News | 0
UK group Kymab has unveiled what it says are “remarkable” early stage results for its new antibody therapy KY1005 in animal models of acute graft-versus-host-disease (GvHD).
Read Moreby Selina McKee | Aug 23, 2016 | News | 0
European regulators have issued a green light for the use of Gilead’s Truvada to cut the risk of HIV infection in adults.
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
